The Cardiovascular Market Outlook to 2011

Publication Date	January 2007
Publisher	Business Insights
Product Type	Report
Pages	126
ISBN Number	not applicable
Product Code	RBI00107

Price

£1,495.00
approximately: $2,185 | €1,638

PDF

PRINT £1,545 ($2,258 | €1,693)

Order above formats by FAX

Summary

The Cardiovascular Market Outlook to 2011 is a new report from Business Insights providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market.

This report offers insight into R&D trends in the cardiovascular market, including the discontinuation of key pipeline drugs such as Pfizer's torcetrapib and atorvastatin, and the development of new drug classes including Novartis' Rasilez (aliskiren), anticipated to be the first to market direct renin inhibitor.

Use this report to identify the leading cardiovascular companies to 2011 and discover the cardiovascular blockbusters of the future.

Key findings of the report...

Anti-hypertensives have been the highest selling portion of the cardiovascular market in 2005. Norvasc was the leading anti-hypertensive drug in 2005, with sales of $5bn, an increase of 3.9% from 2004.
In 2006 the patents protecting Zocor and Pravachol expired, which together with the anticipated patent expiry of Lipitor in 2010, will result in a flood of generic statins onto the market, heavily impacting sales of branded drugs.
Two key anti-hypertensives are forecast to launch in 2007: Novartis' Rasilez (aliskiren) and Exforge (valsartan plus amlodipine). Exforge gained FDA approval in December 2006 and is predicted to generate high sales.
Pfizer's torcetrapib and atorvastatin was discontinued in late 2006 due to safety concerns. The discontinuation of torcetrapib will have an impact on the other members of the CETP inhibitor pipeline drugs, in particular Roche's JTT-705.
Pfizer is the leading global cardiovascular company, with sales of nearly $20bn in 2005, representing 15.6% of the cardiovascular market.
The largest growth seen in the cardiovascular market is from Amgen at 17.4%, with sales in 2005 of $6.4bn.

Key questions answered in this report

What were the key events in the global cardiovascular market in 2005-06?
What are the drivers and resistors to growth for the key players in the market?
How has the failure of key pipeline products expected to impact the global cardiovascular market?
What strategies are the leading companies implementing to maximize sales and boost market share?
When will generic competition impact the leading cardiovascular brands?
Which new product launches are forecast to gain blockbuster status?
What will the competitive landscape in hypertension, thrombosis, dyslipidemia and arrhythmia look like in 2011?

Top five reasons to order your copy today

Gain up-to-date competitive intelligence across the cardiovascular area and understand the major issues affecting key pharmaceutical marketers.
Understand which cardiovascular indications have the greatest potential for growth through the 6-year forecasts in anti-hypertensive, anti-dyslipidemic, anti-thrombosis and cardiac therapy drug classes.
Assess your potential competitive position to the leading cardiovascular companies, through the report's extensive pipeline insight and profiles of upcoming launches.
Examine factors impacting pipeline drugs, such as clinical trial results, discontinued products and patient potentials.
Identify the critical success factors for your company to succeed in the cardiovascular market, through examination of winning growth strategies used by the leading players.

Content

Executive Summary
- Patient potential
- Global cardiovascular market analysis
- Analysis of potential future cardiovascular blockbusters
- Leading players in the cardiovascular market
Chapter 1 Patient potential
- Summary
- Introduction
- Cardiovascular risk factors
- Hypertension
- Dyslipidemia
- Diabetes
- Cardiovascular disease
- Acute thrombotic events
- Acute coronary syndromes
- Venous thromboembolism
- Stroke
- Cardiovascular procedures
- Percutaneous transluminal coronary angioplasty
- Coronary artery bypass grafting
- Insertion of implantable cardioverter defibrillator
- Heart transplantation
Chapter 2 Global cardiovascular market analysis
- Summary
- Introduction
- Key events in the global cardiovascular market, 2005-6
- Pfizer discontinues torcetrapib development
- Genomics and new therapeutic targets
- New therapeutic targets
- Use of biomarkers/pharmacogenomics
- Stem cells
- Genomics
- Market analysis by country
- Market analysis by therapy area
- Leading brands in the global cardiovascular market
- Anti-hypertensives
- Introduction
- Analysis of the leading anti-hypertensives
- Market analysis by drug class
- ACE inhibitors
- Calcium channel blockers
- Angiotensin receptor blockers
- Beta blockers
- Diuretics
- Other hypertension drugs
- Anti-hypertensives sales forecasts
- Anti-dyslipidemics
- Introduction
- Analysis of the leading anti-dyslipidemics
- Market analysis by drug class
- Statins
- Fibrates
- Non-statin products
- Anti-dyslipidemic sales forecasts
- Anti-thrombotics
- Introduction
- Analysis of the leading anti-thrombotics
- Market analysis by drug class
- Anti-platelets
- Heparins
- Vitamin K antagonists
- Fibrinolytics
- Anti-thrombotics sales forecasts
- Cardiac therapies
- Introduction
- Analysis of the leading cardiac therapies
- Market analysis by drug class
- Other cardiac therapies
- Nitrites and nitrates
- Anti-arrhythmics
- Cardiac therapies sales forecast
- v Chapter 3 Analysis of potential future cardiovascular blockbusters
- Summary
- Introduction
- Anti-hypertensives
- Rasilez
- Exforge
- CHF-1521
- Zanipress
- Clevelox
- Cardoxal
- Anti-dyslipidemics
- KS-01-019
- Synordia
- Anti-thrombotics
- BAY-597939
- Rendix
- Idraparinux
- Apixaban
- SSR-126517
- Cardiac therapies
- Multaq
- Stedicor
- RSD1235
- Laszarin
Chapter 4 Leading players in the cardiovascular market
- Summary
- Introduction
- Global market shares
- Pfizer
- Marketed products
- R&D pipeline
- Cardiovascular portfolio sales forecasts
- Strategic analysis
- Drivers of growth
- Resistors of growth
- M&A and licensing activity
- Merck & Co.
- Marketed products
- vi R&D pipeline
- Cardiovascular portfolio sales forecasts
- Strategic analysis
- Drivers of growth
- Resistors of growth
- M&A and licensing activity
- Sanofi-Aventis
- Marketed products
- R&D pipeline
- Cardiovascular portfolio sales forecasts
- Strategic analysis
- Drivers of growth
- Resistors of growth
- M&A and licensing activity
- Novartis
- Marketed products
- R&D pipeline
- Cardiovascular portfolio sales forecasts
- Strategic analysis
- Drivers of growth
- Resistors of growth
- M&A and licensing activity
- Bristol-Myers Squibb
- Marketed products
- R&D pipeline
- Cardiovascular portfolio sales forecasts
- Strategic analysis
- Drivers of growth
- Resistors of growth
- M&A and licensing activity
Chapter 5 Appendix
- IMS data
- Index
List of Figures
- Figure 1.1: Interaction of cardiovascular risk factors
- Figure 2.2: Competitive dynamics of the cardiovascular market, 2004-5
- Figure 2.3: Competitive dynamics of the leading anti-hypertensives, 2004-5
- Figure 2.4: Competitive dynamics of the leading anti-dyslipidemics, 2004-5
- Figure 2.5: Competitive dynamics of the leading anti-thrombotics, 2004-5
- Figure 2.6: Competitive dynamics of the leading cardiac therapies, 2004-5
- Figure 4.7: Leading players in the cardiovascular market, 2004-5
List of Tables
- Table 1.1: Prevalence of hypertension in the 7 major markets, 2005
- Table 1.2: Forecast prevalence of hypertension in the 7 major markets, 2006-11
- Table 1.3: Lipoprotein families
- Table 1.4: Prevalence of dyslipidemia in the 7 major markets, 2005
- Table 1.5: Forecast prevalence of dyslipidemia in the 7 major markets, 2006-15
- Table 1.6: Prevalence of diabetes in the 7 major markets, 2005
- Table 1.7: Forecast prevalence of diabetes in the 7 major markets, 2006-11
- Table 1.8: Prevalence of cardiovascular disease in the 7 major markets, 2005
- Table 1.9: Forecast prevalence of cardiovascular disease in the 7 major markets, 2006-11
- Table 1.10: Prevalence of acute coronary syndromes in the 7 major markets, 2005
- Table 1.11: Estimated incidence of VTE in the seven major markets, 2005
- Table 1.12: Forecast incidence of VTE in the 7 major markets, 2006-11
- Table 1.13: Incidence of stroke in the 7 major markets, 2005
- Table 1.14: Forecast incidence of stroke in the 7 major markets, 2006-2011
- Table 1.15: Prevalence of heart transplants in the US, 2000-5
- Table 2.16: Global cardiovascular sales, 2004-5
- Table 2.17: Global sales of key cardiovascular therapy areas, 20012005
- Table 2.18: Global top 10 selling cardiovascular products, 2005
- Table 2.19: Sales of the leading anti-hypertensives, 2004-5
- Table 2.20: Patent expiries for anti-hypertensive drugs, 2006
- Table 2.21: Anti-hypertensive sales by drug class, 2004-5
- Table 2.22: Sales of the leading ACE inhibitors, 2004-5
- Table 2.23: Sales of the leading CCBs, 2004-5
- Table 2.24: Sales of the leading ARBs, 2004-5
- Table 2.25: Sales of the leading beta blockers, 2004-5
- Table 2.26: Sales of the leading diuretics, 2004-5
- Table 2.27: Anti-hypertensives sales forecast, 2004-11
- Table 2.28: Sales of the leading anti-dyslipidemics, 200405
- Table 2.29: Anti-dyslipidemic sales by drug class, 2004-5
- Table 2.30: Anti-dyslipidemics sales forecast, 2004-11
- Table 2.31: Sales of the leading anti-thrombotics, 2004-5
- Table 2.32: Anti-thrombotic sales by drug class, 2004-5
- Table 2.33: Sales of the leading anti-platelets, 200405
- Table 2.34: Sales of the leading heparins, 200405
- Table 2.35: Anti-thrombotics sales forecast, 2004-11
- Table 2.36: Sales of the leading cardiac therapies, 200405
- Table 2.37: Cardiac therapies sales forecast, 2004-11
- Table 3.38: Anti-hypertensives key late stage pipeline, 2006
- Table 3.39: Anti-dyslipidemics key late stage pipeline, 2006
- Table 3.40: Anti-thrombotic key late stage pipeline, 2006
- Table 3.41: Cardiac therapy key late stage pipeline, 2006
- Table 4.42: Leading players in the cardiovascular market, 2004-5
- Table 4.43: Pfizer's global cardiovascular portfolio, 2004-5
- Table 4.44: Pfizer's cardiovascular pipeline, 2006
- Table 4.45: Forecast sales for Pfizer's cardiovascular portfolio, 200411
- Table 4.46: Merck's global cardiovascular portfolio, 2004-5
- Table 4.47: Merck's cardiovascular pipeline, 2006
- Table 4.48: Forecast sales for Merck's cardiovascular portfolio, 200411
- Table 4.49: Sanofi-Aventis' marketed portfolio, 2004-5
- Table 4.50: Sanofi-Aventis' cardiovascular pipeline, 2006
- Table 4.51: Forecast sales for Sanofi-Aventis' cardiovascular portfolio, 200411
- Table 4.52: Novartis' cardiovascular portfolio, 2004-5
- Table 4.53: Novartis' cardiovascular pipeline, 2006
- Table 4.54: Forecast sales for Novartis' cardiovascular portfolio, 200411
- Table 4.55: Bristol-Myers Squibb's cardiovascular portfolio, 2004-5
- Table 4.56: Bristol-Myers Squibb's cardiovascular pipeline, 2006
- Table 4.57: Forecast sales for Bristol-Myers Squibb's cardiovascular portfolio, 200411